Meeting
2023 ASCO Genitourinary Cancers Symposium
Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
Authors
Mehmet Asim Bilen
Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA
Mehmet Asim Bilen , Ibrahim Khilfeh , Carmine Rossi , Erik Muser , Laura Morrison , Annalise Hilts , Dexter Waters , Patrick Lefebvre , Dominic Pilon , Daniel J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 80)
DOI
10.1200/JCO.2023.41.6_suppl.80
Abstract #
80
Poster Bd #
C8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).
First Author: Pedro C. Barata
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).
First Author: Vivek Narayan
Poster
2020 Genitourinary Cancers Symposium
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
First Author: Johann S. De Bono
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).
First Author: Daniel Triner